Novartis AG Sponsored ADR pharmaceutical (NVS.US) anti-BAFF-R monoclonal antibody two Phase III studies successful.

11/08/2025

Novartis Pharmaceuticals (NVS.US) successfully completed two Phase III studies on the anti-BAFF-R monoclonal antibody.

On August 11, Novartis AG Sponsored ADR Pharmaceutical (NVS.US) announced that two Phase III studies (NEPTUNUS-1 and NEPTUNUS-2) of Ianalumab (VAY736) for the treatment of active Sjgren's syndrome have shown positive results. The drug is expected to become the first targeted therapy for Sjgren's syndrome. Ianalumab is a fully human monoclonal antibody targeting B lymphocyte activation factor receptor (BAFF-R) acquired by Novartis AG Sponsored ADR through the acquisition of MorphoSys. It has a dual mechanism of action of depleting B cells and inhibiting BAFF-R, and can be used to treat a variety of autoimmune diseases such as Sjgren's syndrome, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). This drug is the first anti-BAFF-R antibody to complete Phase III studies.

PHOENITRON HOLD (08066) exercised its share purchase rights to issue 31.27925 million shares.

In the first seven months of 2021, POU SHENG INT'L (03813) had a net operating income of 10.3135 billion yuan, a year-on-year decrease of 8.3%.

CICC: Lower target price of XIAOMI-W(01810) to 70 Hong Kong dollars, expected adjusted net profit to increase by 64.8% in the second quarter.

PHOENITRON HOLD (08066) exercised its share purchase rights to issue 31.27925 million shares.

In the first seven months of 2021, POU SHENG INT'L (03813) had a net operating income of 10.3135 billion yuan, a year-on-year decrease of 8.3%.

CICC: Lower target price of XIAOMI-W(01810) to 70 Hong Kong dollars, expected adjusted net profit to increase by 64.8% in the second quarter.